• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data
【24h】

Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

机译：抗病毒治疗后丙型肝炎引起的肝外并发症的改善：德国疾病基金数据的回顾性分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionGerman data regarding the economic burden of chronic hepatitis C (CHC) and potential benefits of CHC treatment are limited. To address this issue, we evaluated the role of treatment in mitigating the economic burden of hepatic and extrahepatic complications (EHCs) from CHC virus infection in Germany. MethodsThis retrospective, cross-sectional study used claims data from the Betriebskrankenkasse German sickness fund (2007–2014) to assess the medical costs of hepatic complications and EHCs, including conditions that are prevalent and behavioral factors associated with CHC. All-cause costs, medical costs related to hepatic and EHCs, and CHC-related and non-CHC-related pharmacy costs (adjusted to the 2016 euro rate) were calculated and compared between CHC patients’ treated ( n =?1714) and untreated time ( n =?7124) and CHC patients that initiated treatment early (i.e., without cirrhosis; n =?1552) vs. late (i.e., with cirrhosis; n =?162). ResultsCHC treatment was associated with an average adjusted savings of €1885 in annual all-cause medical costs per patient, with a significant proportion attributed to EHC-related cost savings (adjusted difference, €1363; P ConclusionCHC is associated with a significant economic burden in Germany, largely due to EHCs. Antiviral treatment may reduce the burden of CHC and result in significant cost savings, even when initiated at earlier stages of liver disease. FundingAbbVie Inc.
机译：简介关于慢性丙型肝炎（CHC）的经济负担和CHC治疗的潜在益处的德国数据有限。为了解决这个问题，我们评估了治疗在减轻德国CHC病毒感染引起的肝外并发症（EHC）的经济负担方面的作用。方法：这项回顾性的横断面研究使用了德国疾病基金会（Betriebskrankenkasse）的疾病索赔数据（2007-2014年）来评估肝并发症和EHC的医疗费用，包括普遍存在的疾病和与CHC相关的行为因素。计算所有原因成本，与肝脏和EHC相关的医疗成本以及CHC相关和非CHC相关的药房成本（根据2016欧元汇率调整），并比较CHC患者接受治疗的患者（n = 1714）和未经治疗的患者时间（n = 7124）和开始治疗（早期，即无肝硬化; n = 1552）与晚期开始（即，有肝硬化; n = 162）的CHC患者。结果CHC治疗与每位患者每年因各种原因引起的平均医疗费用平均节省1885欧元相关，其中很大一部分归因于EHC相关的成本节省（调整后的差额为1363欧元; P结论）德国，很大程度上是由于EHCs引起的，即使在肝病的早期阶段进行抗病毒治疗也可以减轻CHC的负担并节省大量成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号